02Aug 2022
Durable response in a patient with recurrent respiratory papillomatosis treated with immune checkpoint blockade

Durable response in a patient with recurrent respiratory papillomatosis treated with immune checkpoint blockade

Immune checkpoint blockade can provide clinical benefit for patients with advanced cancer. Here, the study report durable disease control over many years following PD‐L1 blockade through induction of a viral antigen‐specific T cell response in an adult patient with recurrent respiratory papillomatosis. Although demonstrated in a single exceptional responder, these results highlight that immune checkpoint blockade may induce durable, viral antigen‐specific immunity of sufficient magnitude to control disease in patients with nonmalignant disorders.

  • #ent

Like

Save

Share